Beijing 's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruvica (ibrutinib). In the trial, BeiGene's Brukinsa® (zanubrutinib) produced a 78.3% overall response rate compared to imbrutinib's 62.5%. The trial was conducted in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The progression free survival rate at 12 months was 94.9% in the Brukinsa arm, compared to 84.0% in the ibrutinib arm. More details.... Stock Symbol: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //